CLINICAL TRIAL

RUSH2A

Retinal RED

Observational

Early Phase 1

Rate of Progression in USH2A Related Retinal Degeneration

Rare Eye Disease concerned by the trial :
Retinitis pigmentosa, Usher Syndrome

Status of the trial : recruiting

Orphan drug recognition : N/A

Inclusion criteria : Participants with clinical diagnosis of rod-cone degeneration and at least 2 pathogenic or likely pathogenic mutations in USH2A gene; age ≥ 8 years

Exclusion criteria : Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than USH2A; Expected to enter experimental treatment trial at any time during this study; History of more than 1 year of cumulative treatment, at any time, with an agent 431 associated with pigmentary retinopathy.

Inclusion opening date : 01/08/2017

Inclusion closing date (previsional) : 31/12/2021

Children ☑

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Center for Ophthalmology, University of Tübingen
Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

Contact details

Principal investigator name :
Katarina Stingl

Other investigators :

Radboud University Medical Center,
Nijmegen, Netherlands

Department of Ophthalmology, UCSF
San Francisco, CA, USA
Jacque Duncan



Funder type : Patient organization

More informations